DRNA - Dicerna Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

Dicerna Pharmaceuticals's activity chart (see below) currently has 94 price targets and 69 ratings on display.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 77.34% with an average time for these price targets to be met of 369.08 days.

Most recent stock forecast was given by from CHARDAN CAPITAL on 10-Dec-2021. First documented stock forecast 13-Mar-2015.

Best performing analysts who are covering DRNA - Dicerna Pharmaceuticals:

Mani Foroohar Mayank Mamtani Yigal Nochomovitz Madhu Kumar Robyn Karnauskas

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 02-Mar-2021

$38.25

$0.03 (0.08%)

$28

4 years 8 months 30 days ago
(10-Dec-2021)

2/3 (66.67%)

$0.34 (0.90%)

101

Buy Since 13-May-2020

$38.25

4 years 9 months 20 days ago
(20-Nov-2021)

3/3 (100%)

$0.33 (0.87%)

171

Buy Since 13-Sep-2018

$38

4 years 9 months 21 days ago
(19-Nov-2021)

9/11 (81.82%)

$-0.03 (-0.08%)

277

Buy Since 12-Mar-2019

$35

$-3.22 (-8.42%)

$35

4 years 9 months 22 days ago
(18-Nov-2021)

4/7 (57.14%)

$-3.03 (-7.97%)

243

Buy Since 06-Nov-2018

$25

5 years 29 days ago
(11-Aug-2021)

6/10 (60%)

$2.81 (12.66%)

241

Show more analysts

Please expand the browser size to see the chart

What is DRNA (Dicerna Pharmaceuticals) average time for price targets to be met?

On average it took 369 days for the stock forecasts to be reached, with an average price target met ratio of 77.34%.

Which analyst most recently updated their price target on DRNA (Dicerna Pharmaceuticals)?

Which analyst has the most public recommendations on DRNA (Dicerna Pharmaceuticals)?

has 0 price targets and 0 ratings on DRNA

Which analyst is the currently most bullish on DRNA (Dicerna Pharmaceuticals)?

Keay Nakae with the highest potential upside of $0.03

Which analyst is the currently most reserved on DRNA (Dicerna Pharmaceuticals)?

Eun Yang with the lowest potential downside of -$31.22

To continue looking at which analysts cover the stock please register to the basic or advanced membership

To continue looking at analysts data please register to the advanced membership

What is AnaChart?